Table 1.
Drug (Class) | N | Safety Signal 5 for BD | Date of FDA Approval |
---|---|---|---|
Nivolumab (PD-1) | 99 | Yes | Dec 22, 2014 |
Pembrolizumab (PD-1) | 43 | Yes | Sep 2, 2014 |
Atezolizumab (PD-L1) | 7 | Yes | May 18, 2016 |
Durvalumab (PD-L1) | 4 | Yes | May 1, 2017 |
Avelumab (PD-L1) | 0 | No | Mar 23, 2017 |